Posted by Michael Wonder on 04 Aug 2016
NICE issues draft guidance on the use of lesinurad
3 August 2016 - NICE has issued draft guidance on the use of lesinurad (Zurampic) for the treatment of patients with hyperuricaemia.
Lesinurad, in combination with a xanthine oxidase inhibitor, is not recommended for treating hyperuricaemia in adults with gout whose serum uric acid is above the target level despite an adequate dose of a xanthine oxidase inhibitor alone.
Lesinurad will be considered at a second appraisal committee meeting on 7 September 2016.
